[Roaming through methodology. XXV. Outcome measures, surrogate outcomes, and intermediate measures]
- PMID: 11048558
[Roaming through methodology. XXV. Outcome measures, surrogate outcomes, and intermediate measures]
Abstract
Clinical medicine is aimed at decreasing the current or future burden of disease. Disease outcome is best expressed as burden of disease or change thereof, and as such the only true 'outcome measure' in clinical research. However, outcome research is expensive in costs and time expenditure, and sometimes impossible. Therefore study results are often expressed in intermediate measures. These measures tell us something about the disease process and the pathophysiological consequences of the disease and should have a relation with outcome. If this relation is strong, the measure is called 'surrogate outcome'. Intermediate measures and surrogate outcomes have advantages and disadvantages. The reader of clinical trial results first has to decide whether the answer to the study question is relevant in his personal situation. If so, the applicability of a measure can be simply appraised by answering 3 questions: 'Is the measure truthful (relevant, unbiased)?'; 'Does it discriminate between situations that are of interest?'; 'Is the measure feasible in my setting?'
Similar articles
-
Procedures and methods of benefit assessments for medicines in Germany.Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5. Eur J Health Econ. 2008. PMID: 18987905
-
Outcomes assessment in fracture healing trials: a primer.J Orthop Trauma. 2010 Mar;24 Suppl 1:S71-5. doi: 10.1097/BOT.0b013e3181ca3fbd. J Orthop Trauma. 2010. PMID: 20182241 Review.
-
[Procedures and methods of benefit assessments for medicines in Germany].Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. doi: 10.1055/s-0028-1100954. Epub 2008 Nov 25. Dtsch Med Wochenschr. 2008. PMID: 19034813 German.
-
Understanding clinical trial outcomes: design, analysis, and interpretation.Dermatol Ther. 2007 Mar-Apr;20(2):77-85. doi: 10.1111/j.1529-8019.2007.00115.x. Dermatol Ther. 2007. PMID: 17537135
-
Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.J Natl Cancer Inst Monogr. 2004;(33):78-101. doi: 10.1093/jncimonographs/lgh016. J Natl Cancer Inst Monogr. 2004. PMID: 15504921 Review.